Abstract
| Original language | English |
|---|---|
| Journal | Alimentary Pharmacology and Therapeutics |
| DOIs | |
| Publication status | E-pub ahead of print - Oct 28 2016 |
Fingerprint
Cite this
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. / Petta, S.; Cabibbo, G; Barbara, M; Attardo, S; Bucci, L.; Farinati, F; Giannini, E.G.; Tovoli, Francesco; Ciccarese, F.; Rapaccini, G. L.; Di Marco, M.; Caturelli, Eugenio; Zoli, M.; Borzio, F.; Sacco, R.; Virdone, Roberto; Marra, F.; Felder, Martina; Morisco, F.; Benvegnù, L.; Gasbarrini, A.; Svegliati Baroni, Gianluca; Foschi, F.G.; Olivani, Andrea; Masotto, Alberto; Nardone, G.; Colecchia, A.; Persico, M.; Boccaccio, Vincenzo; Craxì, Antonio; Bruno, S.; Trevisani, F.; Cammà, C.; Group, the Italian Liver Cancer (ITA.LI.CA); Biselli, Maurizio; Caraceni, P.; Cucchetti, A.; Domenicali, Marco; Piscaglia, Fabio; Gramenzi, A.; Granito, Alessandro; Magalotti, Donatella; Serra, C.; Negrini, Giulio; Napoli, L.; Salvatore, V.; Benevento, Francesca; Gazzola, A.; Murer, Francesca; Pozzan, Caterina; Vanin, V.; Moscatelli, A.; Pellegatta, G.; Picciotto, A.; Savarino, V.; DelPoggio, P.; Olmi, S.; deMatthaeis, Nicoletta; Balsamo, C.; Vavassori, E.; Roselli, P.; Dell’Isola, S.; Ialungo, A. M.; Rastrelli, Elena; Rini, F.; Costantino, A.; Affronti, A.; Affronti, M.; Mascari, M.; Mega, A.; Pompili, M.; Rinninella, Emanuele; Mismas, Valeria; Dall’Aglio, A.C.; Feletti, Valentina; Lanzi, Arianna; Cappa, Federica Mirici; Neri, E.; Stefanini, G.F.; Tamberi, Stefano; Biasini, E.; Missale, G.; GUARINO, M.; Ortolani, A.; Chiaramonte, M.; Marchetti, F.; Valerio, M.; Aburas, S.; Inghilesi, A.L.; Cappelli, A.; Golfieri, Rita; Mosconi, Cristina; Renzulli, Matteo; Coccoli, P.; Zamparelli, M.S.; Dimarco, Mariacristina.
In: Alimentary Pharmacology and Therapeutics, 28.10.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon
AU - Petta, S.
AU - Cabibbo, G
AU - Barbara, M
AU - Attardo, S
AU - Bucci, L.
AU - Farinati, F
AU - Giannini, E.G.
AU - Tovoli, Francesco
AU - Ciccarese, F.
AU - Rapaccini, G. L.
AU - Di Marco, M.
AU - Caturelli, Eugenio
AU - Zoli, M.
AU - Borzio, F.
AU - Sacco, R.
AU - Virdone, Roberto
AU - Marra, F.
AU - Felder, Martina
AU - Morisco, F.
AU - Benvegnù, L.
AU - Gasbarrini, A.
AU - Svegliati Baroni, Gianluca
AU - Foschi, F.G.
AU - Olivani, Andrea
AU - Masotto, Alberto
AU - Nardone, G.
AU - Colecchia, A.
AU - Persico, M.
AU - Boccaccio, Vincenzo
AU - Craxì, Antonio
AU - Bruno, S.
AU - Trevisani, F.
AU - Cammà, C.
AU - Group, the Italian Liver Cancer (ITA.LI.CA)
AU - Biselli, Maurizio
AU - Caraceni, P.
AU - Cucchetti, A.
AU - Domenicali, Marco
AU - Piscaglia, Fabio
AU - Gramenzi, A.
AU - Granito, Alessandro
AU - Magalotti, Donatella
AU - Serra, C.
AU - Negrini, Giulio
AU - Napoli, L.
AU - Salvatore, V.
AU - Benevento, Francesca
AU - Gazzola, A.
AU - Murer, Francesca
AU - Pozzan, Caterina
AU - Vanin, V.
AU - Moscatelli, A.
AU - Pellegatta, G.
AU - Picciotto, A.
AU - Savarino, V.
AU - DelPoggio, P.
AU - Olmi, S.
AU - deMatthaeis, Nicoletta
AU - Balsamo, C.
AU - Vavassori, E.
AU - Roselli, P.
AU - Dell’Isola, S.
AU - Ialungo, A. M.
AU - Rastrelli, Elena
AU - Rini, F.
AU - Costantino, A.
AU - Affronti, A.
AU - Affronti, M.
AU - Mascari, M.
AU - Mega, A.
AU - Pompili, M.
AU - Rinninella, Emanuele
AU - Mismas, Valeria
AU - Dall’Aglio, A.C.
AU - Feletti, Valentina
AU - Lanzi, Arianna
AU - Cappa, Federica Mirici
AU - Neri, E.
AU - Stefanini, G.F.
AU - Tamberi, Stefano
AU - Biasini, E.
AU - Missale, G.
AU - GUARINO, M.
AU - Ortolani, A.
AU - Chiaramonte, M.
AU - Marchetti, F.
AU - Valerio, M.
AU - Aburas, S.
AU - Inghilesi, A.L.
AU - Cappelli, A.
AU - Golfieri, Rita
AU - Mosconi, Cristina
AU - Renzulli, Matteo
AU - Coccoli, P.
AU - Zamparelli, M.S.
AU - Dimarco, Mariacristina
N1 - Cited By :1 Export Date: 21 March 2017 CODEN: APTHE Correspondence Address: Cammà, C.Italy; email: calogero.camma@unipa.it References: Ferlay, J., Shin, H.R., Bray, F., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 (2010) Int J Cancer, 127, pp. 2893-2917; Alazawi, W., Cunningham, M., Dearden, J., Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection (2010) Aliment Pharmacol Ther, 32, pp. 344-355; Bucci, L., Garuti, F., Camelli, V., Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome (2016) Aliment Pharmacol Ther, 43, pp. 385-399; EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma (2012) J Hepatol, 56, pp. 908-943; Bruix, J., Reig, M., Sherman, M., Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma (2016) Gastroenterology, 150, pp. 835-853; 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma (2015) Gut Liv, 9, pp. 267-317; Mazzaferro, V., Lencioni, R., Majno, P., Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation (2014) Semin Liver Dis, 34, pp. 415-426; Llovet, J.M., Di Bisceglie, A.M., Bruix, J., Design and endpoints of clinical trials in hepatocellular carcinoma (2008) J Natl Cancer Inst, 100, pp. 698-711; Cabibbo, G., Reig, M., Gadaleta-Caldarola, G., The calm before the storm: a report from the International Liver Cancer Association Congress 2015 - part 2 (2016) Future Oncol, 12, pp. 285-288; Bruix, J., Takayama, T., Mazzaferro, V., Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial (2015) Lancet Oncol, 16, pp. 1344-1354; Di Marco, V., Calvaruso, V., Ferraro, D., Effects of viral eradication in patients with hepatitis C virus and cirrhosis differ with stage of portal hypertension (2016) Gastroenterology, 151, pp. 130-139; Petta, S., Di Marco, V., Bruno, S., Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model (2016) Liver Int, , [Epub ahead of print]; Miyake, Y., Takaki, A., Iwasaki, Y., Yamamoto, K., Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma (2010) J Viral Hepat, 17, pp. 287-292; Singal, A.K., Freeman, D.H., Jr., Anand, B.S., Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma (2010) Aliment Pharmacol Ther, 32, pp. 851-858; Miao, R.Y., Zhao, H.T., Yang, H.Y., Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis (2010) World J Gastroenterol, 16, pp. 2931-2942; Zhuang, L., Zeng, X., Yang, Z., Meng, Z., Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis (2013) PLoS ONE, 8; Zhang, W., Song, T.Q., Zhang, T., Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis (2014) Mol Clin Oncol, 2, pp. 1125-1134; Reig, M., Mariño, Z., Perelló, C., Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution (2016) J Hepatol, 65, pp. 719-726; Conti, F., Buonfiglioli, F., Scuteri, A., Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals (2016) J Hepatol, 65, pp. 727-733; Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Transection of the oesophagus for bleeding oesophageal varices (1973) Br J Surg, 60, pp. 646-649; Malinchoc, M., Kamath, P.S., Gordon, F.D., A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts (2000) Hepatology, 31, pp. 864-871; Garcia-Tsao, G., Sanyal, A.J., Grace, N.D., Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis (2007) Hepatology, 46, pp. 922-938; Oken, M.M., Creech, R.H., Tormey, D.C., Toxicity and response criteria of the Eastern Cooperative Oncology Group (1982) Am J Clin Oncol, 5, pp. 649-655; Mazzaferro, V., Regalia, E., Doci, R., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis (1996) N Engl J Med, 334, pp. 693-699; Suou, T., Mitsuda, A., Koda, M., Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study (2001) Hepatol Res, 20, pp. 301-311; Jeong, S.C., Aikata, H., Katamura, Y., Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma (2007) World J Gastroenterol, 13, pp. 5343-5350; Kanogawa, N., Ogasawara, S., Chiba, T., Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor (2015) J Gastroenterol Hepatol, 30, pp. 1197-1204; Cammà, C., Cabibbo, G., Craxì, A., Direct antiviral agents and risk for hepatocellular carcinoma early recurrence: much ado about nothing (2016) J Hepatol, 65, pp. 861-862; Rohatgi, A., WebPlotDigitizer, , http://arohatgi.info/WebPlotDigitizer, (accessed May 2016); Giannini, E.G., Sammito, G., Farinati, F., Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use (2014) Cancer, 120, pp. 2150-2157; Tatsumi, T., Takehara, T., Impact of NK cells on chronic hepatitis C and hepatocellular carcinoma (2016) Hepatol Res, 46, pp. 416-422; Brownell, J., Polyak, S.J., Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer (2013) Clin Cancer Res, 19, pp. 1347-1352
PY - 2016/10/28
Y1 - 2016/10/28
N2 - Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P <0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used. © 2016 John Wiley & Sons Ltd
AB - Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P <0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used. © 2016 John Wiley & Sons Ltd
U2 - 10.1111/apt.13821
DO - 10.1111/apt.13821
M3 - Article
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
ER -